| 二肽基肽酶-4抑制药研究进展 |
| |
| 引用本文： | 曹凤,吴方建. 二肽基肽酶-4抑制药研究进展[J]. 中国药师, 2014, 0(4): 667-670 |
| |
| 作者姓名： | 曹凤 吴方建 |
| |
| 作者单位： | 长江航运总医院药剂科 武汉 430010;长江航运总医院药剂科 武汉 430010 |
| |
| 摘 要： | 二肽基肽酶-4（DPP-4）抑制药是一类新型口服降糖药，可改善血糖控制，并且不会增加体质量和诱发低血糖，在2型糖尿病的治疗中发挥着越来越重要的作用。本文对DPP-4抑制药作用机制、药动学及临床应用等方面的研究进展进行综述，以期为临床应用提供一定参考。
|
| 关 键 词： | 二肽基肽酶-4抑制药 2型糖尿病 研究进展 |
| 收稿时间： | 2013-11-12 |
| 修稿时间： | 2013-12-29 |
Research Progress in Dipeptidyl Peptidase-4 Inhibitors |
| |
| Cao Feng and Wu Fangjian. Research Progress in Dipeptidyl Peptidase-4 Inhibitors[J]. China Pharmacist, 2014, 0(4): 667-670 |
| |
| Authors: | Cao Feng and Wu Fangjian |
| |
| Affiliation: | Department of Pharmacy, General Hospital of Yangtze River Shipping, Wuhan 430010, China;Department of Pharmacy, General Hospital of Yangtze River Shipping, Wuhan 430010, China |
| |
| Abstract: | ABSTRACT Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new kind of oral hypoglycemic drugs, can significantly lower blood glucose levels in the patients with type 2 diabetes without common side effects such as body weight gain, hypoglycemia and gastrointestinal disturbances. Therefore, DPP-4 inhibitors play an increasingly important role in the treatment of type 2 diabetes. In this review, the research progress in the action mechanism, pharmacokinetics and clinical applications of DPP-4 inhibitors was summarized in order to provide reference for the clinical application. |
| |
| Keywords: | DPP-4 inhibitors Type 2 diabetes mellitus Research progress |
| 本文献已被 CNKI 维普 等数据库收录！ |
| 点击此处可从《中国药师》浏览原始摘要信息 |
|
点击此处可从《中国药师》下载免费的PDF全文 |
|
